New: Our latest case study on qFibrosis' role in the successful development of Rezdiffra


Webcast: Fit-for-purpose: The Evolving Role of Liver Biopsies in MASH Clinical Trials and Patient Management

[Full Podcast] Special Episode (Part 2) - Conversation with KOL Liver Pathologists

Date: 17 Mar 2021

Our guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH. 

We’d like to thank our Guests and Moderator for their kind participation and professional views!
Prof. Pierre Bedossa
Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France
Prof. Zachary Goodman
Director of Hepatic Pathology Consultation and Research, Inova Fairfax Hospital, Falls Church, Virginia, USA
Prof. David Kleiner
Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA
Dr. Nikolai Naoumov
Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG
Key Takeaways from the KOLs in this Special Episode (Part 2)
– According to the KOLs, regression of disease is not well delineated or understood. AI-DP offers new insights into the biology of NASH and additional information especially in the identification of ballooned hepatocytes, quantification of peri-sinusoidal fibrosis, septa quantification and others.
– In the assessment of disease biology, it was highlighted that AI-DP can identify morphological/pathological features that cannot be detected by the human eye. This is an area where AI-DP plays a complementary role by providing precise details on liver architecture and reproducible quantitation with new parameters.
– It was stated that it is not appropriate to attempt to quantitate ratio of different patterns like F1 to F4 in a single specimen, as the pathology objective is to provide an integrated assessment.
– It was recommended that the role of AI-DP and the information it provides be regarded as an aid to extend the outputs of pathologists. Instead of being perceived as a replacement of pathologists, AI-DP could be seamlessly integrated into the pathologists’ daily workflow.
We hope that you will enjoy Part 1 and 2 of our Special Episode. Do remember to Subscribe to our Podcast to receive updates on new episodes!